Time is Brain Secures €3 Million and Achieves CE/MDR Approval to Accelerate the Adoption of Real-Time Stroke Intelligence Across Europe
Time is Brain Secures €3 Million and Achieves CE/MDR Approval to Accelerate the Adoption of Real-Time Stroke Intelligence Across Europe
Funding and regulatory approval pave the way for European commercialization through strategic distribution partnerships.
Barcelona, Spain – 10th July 2026 – Time is Brain, pioneering the emerging category of Real-Time Stroke Intelligence, today announced two major milestones supporting its commercial expansion across Europe: the successful closing of an oversubscribed €3 million Pre-Series A financing round and CE/MDR approval
Together, these achievements represent a significant step forward in the company’s mission to help clinicians make faster, more informed stroke decisions through continuous neurological assessment and real-time clinical insight.
The financing will support commercial expansion, distributor onboarding, market access activities and continued clinical evidence generation as Time is Brain prepares for the European rollout of its platform later this year.
Stroke affects more than 10 million people worldwide every year and remains one of the leading causes of death and long-term disability. Every minute of delayed treatment increases the risk of irreversible brain injury. While imaging technologies have transformed stroke diagnosis and treatment, many clinical decisions still rely on information captured at a single point in time.
Time is Brain was founded on the belief that clinicians need more than snapshots—they need continuous neurological insight when every second matters.
“Stroke is one of the few medical emergencies where every minute directly influences a patient’s future. Yet clinicians often make critical decisions using information captured at a single moment in time,“said Dr. Alicia Martinez, neurologist, Co-Founder and CEO of Time is Brain. “We believe the future of stroke care will combine imaging with continuous neurological intelligence, helping clinicians make faster, more informed decisions when every second matters. CE/MDR approval and this investment allow us to bring that vision into clinical practice across Europe.“
Time is Brain remains committed to transforming neurocritical care through innovation, precision, and collaboration.
